INCY Incyte Corp

Price (delayed)

$53.22

Market cap

$11.95B

P/E Ratio

19.93

Dividend/share

N/A

EPS

$2.67

Enterprise value

$8.77B

Incyte Corp is an American pharmaceutical company based in Alapocas, Delaware. The company was founded in Palo Alto, California in 1991 and went public in 1993. Incyte has one drug, ...

Highlights
INCY's net income has soared by 75% year-on-year and by 41% since the previous quarter
INCY's EPS has soared by 75% YoY and by 41% QoQ
The company's quick ratio rose by 6% YoY but it fell by 4.3% QoQ
The debt is up by 2.1% since the previous quarter

Key stats

What are the main financial stats of INCY
Market
Shares outstanding
224.53M
Market cap
$11.95B
Enterprise value
$8.77B
Valuations
Price to book (P/B)
2.3
Price to sales (P/S)
3.22
EV/EBIT
10.48
EV/EBITDA
9.53
EV/Sales
2.37
Earnings
Revenue
$3.7B
EBIT
$836.77M
EBITDA
$919.43M
Free cash flow
$464M
Per share
EPS
$2.67
Free cash flow per share
$2.07
Book value per share
$23.16
Revenue per share
$16.53
TBVPS
$29.08
Balance sheet
Total assets
$6.78B
Total liabilities
$1.59B
Debt
$32.6M
Equity
$5.19B
Working capital
$3.41B
Liquidity
Debt to equity
0.01
Current ratio
3.75
Quick ratio
3.55
Net debt/EBITDA
-3.46
Margins
EBITDA margin
24.9%
Gross margin
93.1%
Net margin
16.2%
Operating margin
16.8%
Efficiency
Return on assets
9.5%
Return on equity
12.4%
Return on invested capital
46.1%
Return on capital employed
15.1%
Return on sales
22.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INCY stock price

How has the Incyte stock price performed over time
Intraday
-0.39%
1 week
-3.76%
1 month
-8.82%
1 year
-28.56%
YTD
-15.24%
QTD
-6.58%

Financial performance

How have Incyte's revenue and profit performed over time
Revenue
$3.7B
Gross profit
$3.44B
Operating income
$620.53M
Net income
$597.6M
Gross margin
93.1%
Net margin
16.2%
INCY's net income has soared by 75% year-on-year and by 41% since the previous quarter
The net margin has soared by 62% year-on-year and by 37% since the previous quarter
Incyte's operating income has increased by 23% from the previous quarter and by 7% YoY
INCY's operating margin is up by 21% since the previous quarter

Growth

What is Incyte's growth rate over time

Valuation

What is Incyte stock price valuation
P/E
19.93
P/B
2.3
P/S
3.22
EV/EBIT
10.48
EV/EBITDA
9.53
EV/Sales
2.37
INCY's EPS has soared by 75% YoY and by 41% QoQ
INCY's P/E is 44% below its last 4 quarters average of 35.4
The stock's price to book (P/B) is 58% less than its 5-year quarterly average of 5.5 and 23% less than its last 4 quarters average of 3.0
INCY's equity is up by 19% year-on-year and by 5% since the previous quarter
INCY's P/S is 48% below its 5-year quarterly average of 6.2 and 20% below its last 4 quarters average of 4.0
Incyte's revenue has increased by 9% YoY and by 2.4% from the previous quarter

Efficiency

How efficient is Incyte business performance
INCY's return on assets has surged by 51% year-on-year and by 36% since the previous quarter
The ROE has soared by 51% YoY and by 35% from the previous quarter
INCY's ROS is up by 44% YoY and by 26% QoQ
The ROIC has increased by 38% YoY and by 19% from the previous quarter

Dividends

What is INCY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INCY.

Financial health

How did Incyte financials performed over time
Incyte's total assets has increased by 16% YoY and by 6% from the previous quarter
INCY's total liabilities is up by 9% since the previous quarter and by 8% year-on-year
The debt is 99% smaller than the equity
INCY's equity is up by 19% year-on-year and by 5% since the previous quarter
The debt is up by 2.1% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.